ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AVBP vs ARDX // ENTERPRISE SCALE & MARKET CAP

ArriVent BioPharma Inc. (NASDAQ) VS. Ardelyx Inc. (NASDAQ) • 15-METRIC TALLY: AVBP 1 — ARDX 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: AVBP
market-cap
$786.5M
market-cap
$772.5M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVBP VS. ARDX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AVBP ARDX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 90.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.70% -2.30 ARDX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -20.42% -5.69% -14.73 ARDX /fcf-yield <GO>
Operating Margin — -10.10% — TIE /operating-margins <GO>
Net Profit Margin — -15.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — 22.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 ARDX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.9 42.1 -5.20 ARDX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $786.5M $772.5M $14.0M AVBP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AVBP REV ARDX REV AVBP GROSS % ARDX GROSS % AVBP FCF ARDX FCF
FY 2025 $0 $407.3M — 90.3% -$160.6M -$44.0M
FY 2024 $0 $333.6M — 84.8% -$70.2M -$45.8M
FY 2023 $0 $124.5M — — -$55.8M -$89.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVBP // BETA —
ARDX // BETA —